5 results
To determine if inhibition with GPB can provide a significant reduction in the accumulation of systemically administered Ga-PSMA in salivary glands on PET/CT, with the aim to determine if GPB can prevent toxicity from Lu-PSMA or other…
Primary: to determine if inhibition with GPB can provide a significant (>30%) reduction in the accumulation of orally administered Iodine-123 in salivary glands, measured at 4h after administraion. Secondary: to determine if a reduction at 4h…
The primary objective is to compare the objective response rate (ORR) per Response Assessment in Neuro Oncology (RANO) criteria assessed by independent review committee (IRC) of DAY101 monotherapy versus standard of care (SoC) chemotherapy in…
Primary: To assess the safety profile of selnoflast compared with that of placeboSecondary: - To evaluate the efficacy of selnoflast compared with that of placebo- To assess the pharmacokinetic properties of selnoflast and metabolite(s) as…
The objective of the study is to assess the safety and tolerability, and to characterize the pharmacokinetics (PK) and pharmacodynamics (e.g., Cerebrospinal fluid [CSF] levels of IL-1β, TSPO positron emission tomography [PET] imaging) of selnoflast…